170 related articles for article (PubMed ID: 33009434)
21. Recurrent pseudohypopyon in association with primary vitreoretinal lymphoma: a case report.
Kitao M; Hashida N; Nishida K
BMC Ophthalmol; 2016 Jul; 16():103. PubMed ID: 27391815
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
23. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
Motomura Y; Yoshifuji K; Tachibana T; Takase H; Arai A; Tanaka K; Okada K; Nogami A; Umezawa Y; Sakashita C; Yamamoto M; Mori T; Nagao T
Br J Haematol; 2024 Apr; 204(4):1279-1287. PubMed ID: 38131400
[TBL] [Abstract][Full Text] [Related]
24. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.
Chan CC; Rubenstein JL; Coupland SE; Davis JL; Harbour JW; Johnston PB; Cassoux N; Touitou V; Smith JR; Batchelor TT; Pulido JS
Oncologist; 2011; 16(11):1589-99. PubMed ID: 22045784
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic methods for primary vitreoretinal lymphoma: A systematic review.
Huang RS; Mihalache A; Popovic MM; Cruz-Pimentel M; Pandya BU; Muni RH; Kertes PJ
Surv Ophthalmol; 2024; 69(3):456-464. PubMed ID: 38163550
[TBL] [Abstract][Full Text] [Related]
26. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.
Jiang T; Gu J; Liu S; Chang Q
BMC Ophthalmol; 2022 Sep; 22(1):375. PubMed ID: 36127675
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single-center real-world clinical experience.
Min GJ; Kim TY; Jeon YW; O JH; Choi BO; Park G; Park YH; Cho SG
Cancer Med; 2023 Apr; 12(7):7911-7922. PubMed ID: 36721307
[TBL] [Abstract][Full Text] [Related]
28. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma.
Raja H; Snyder MR; Johnston PB; O'Neill BP; Caraballo JN; Balsanek JG; Peters BE; Decker PA; Pulido JS
PLoS One; 2013; 8(6):e65627. PubMed ID: 23750271
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes following intravitreal methotrexate for primary vitreoretinal lymphoma.
Anthony CL; Bavinger JC; Shantha JG; O'Keefe GD; Pearce WA; Voloschin A; Grossniklaus HE; Yeh S
Int J Retina Vitreous; 2021 Dec; 7(1):72. PubMed ID: 34863313
[TBL] [Abstract][Full Text] [Related]
30. Gene expression profiling of primary vitreoretinal lymphoma.
Arai A; Takase H; Yoshimori M; Yamamoto K; Mochizuki M; Miura O
Cancer Sci; 2020 Apr; 111(4):1417-1421. PubMed ID: 32056332
[TBL] [Abstract][Full Text] [Related]
31. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
Guneri Beser B; Demirci H
Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
[TBL] [Abstract][Full Text] [Related]
32. Neoplastic lymphomatous submaculopathy.
Testi I; Agarwal A; Gupta V;
Indian J Ophthalmol; 2019 Dec; 67(12):2051-2052. PubMed ID: 31755451
[No Abstract] [Full Text] [Related]
33. Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.
Kaburaki T; Taoka K
Jpn J Ophthalmol; 2023 Jul; 67(4):363-381. PubMed ID: 37209195
[TBL] [Abstract][Full Text] [Related]
34. Primary vitreoretinal natural killer/T-cell lymphoma with breast involvement: A case report and review of the literature.
Gao S; Zhou Y; Jin X; Lin Z; Zhong Y; Shen X
Surv Ophthalmol; 2019; 64(2):225-232. PubMed ID: 30321569
[TBL] [Abstract][Full Text] [Related]
35. Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma.
Wang Y; Shen D; Wang VM; Sen HN; Chan CC
Int J Mol Sci; 2011; 12(9):5684-97. PubMed ID: 22016619
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.
Cheng CL; Yeh PT; Fang WQ; Ma WL; Hou HA; Tsai CH; Lin CP; Tien HF
Cancer Med; 2023 Apr; 12(7):8102-8111. PubMed ID: 36602288
[TBL] [Abstract][Full Text] [Related]
37. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug.
Shields CL; Sioufi K; Mashayekhi A; Shields JA
JAMA Ophthalmol; 2017 Jul; 135(7):815-818. PubMed ID: 28617918
[No Abstract] [Full Text] [Related]
39. Interleukin-10 and interleukin-6 in aqueous humor during treatment of vitreoretinal lymphoma with intravitreally injected methotrexate.
Kawamura H; Yasuda N; Kakinoki M; Sawada T; Sawada O; Ohji M
Ophthalmic Res; 2009; 42(3):172-4. PubMed ID: 19648778
[TBL] [Abstract][Full Text] [Related]
40. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease.
Bae JH; Lee SC
Retina; 2012 Jul; 32(7):1395-402. PubMed ID: 22012204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
